Skip to main content
. Author manuscript; available in PMC: 2009 Dec 11.
Published in final edited form as: J Med Chem. 2008 Dec 11;51(23):7563–7573. doi: 10.1021/jm800997s

Table 4.

Kinetic Parameters and MIC of Aminoglycosides for APH(3′)-IIIa

Compound KM (μM) Vmax
(μmol/mg/min)
kcat (S−1) kcat/KM/104
(S−1M−1)
MIC against
bacterium with
APH(3′)-IIIa a
MIC ratio b
Kanamycin A 8.2±0.7 6.96±0.12 3.48±0.06 42.4 125 (Kan B) 32 (Kan B)
Amikacin 57.4±5.7 2.75±0.13 1.38±0.07 24.0 1 1
Neomycin B 6.0±0.8 3.22±0.17 1.61±0.09 26.8 64 8
4a 160±15 0.41±0.03 0.21±0.02 0.13 125 8
4b 127±13 0.75±0.04 0.38±0.02 0.30 32-64 4
4c 120±14 0.65±0.05 0.33±0.03 0.28 64-125 8
4d 410±38 0.30±0.03 0.15±0.02 0.037 16-32 2
4e 100±9 0.72±0.07 0.36±0.04 0.36 125 8
4f 150±16 0.54±0.05 0.27±0.03 0.18 125 8
4g 111±12 0.68±0.04 0.34±0.02 0.3 64 4
4h 171±18 0.41±0.04 0.21±0.02 0.12 64-125 8
4i 175±18 0.40±0.04 0.20±0.02 0.14 64-125 8
5a 48±6 0.95±0.06 0.48±0.05 1.0 64 8
5b 58±4 0.85±0.08 0.42±0.05 0.72 1-2 0.5
5c 60±7 0.84±0.05 0.42±0.03 0.7 2 1-2
5d 400±35 0.38±0.04 0.19±0.02 0.048 32-64 4
5e 50±4 0.93±0.07 0.47±0.05 0.94 125 8
5f 75±8 0.88±0.06 0.44±0.03 0.6 32 2
5g 60±5 0.90±0.09 0.45±0.05 0.75 64 4
5h 80±9 0.63±0.07 0.32±0.03 0.4 64 4
5i 322±31 0.57±0.06 0.29±0.03 0.1 64 4
5j 42±4 1.01±0.09 0.51±0.05 1.2 32-64 4
5k 78±8 0.79±0.08 0.40±0.03 0.51 32-64 4
5l 53±6 0.86±0.09 0.43±0.04 0.81 250 8
5m 63±7 0.82±0.09 0.41±0.04 0.65 64-125 8
5n 57±6 0.93±0.10 0.47±0.05 0.82 64 4
5o 70±8 0.72±0.07 0.36±0.04 0.51 64 8
5p 75±8 0.70±0.07 0.35±0.04 0.47 64-125 8
33 >500 <0.1 <0.05 <0.01 64-125 8
a

Unit: μg/mL,

b

MIC ratio = (MIC against E. coli (TG1))/(MIC against E. coli (TG1) with APH(3′)-IIIa )